Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
Leukemia, Myelodysplastic Syndromes
About this trial
This is an interventional treatment trial for Leukemia focused on measuring recurrent childhood acute lymphoblastic leukemia, childhood myelodysplastic syndromes, childhood acute lymphoblastic leukemia in remission, recurrent childhood acute myeloid leukemia, childhood acute myeloid leukemia in remission, secondary acute myeloid leukemia, accelerated phase chronic myelogenous leukemia, blastic phase chronic myelogenous leukemia, childhood chronic myelogenous leukemia, relapsing chronic myelogenous leukemia, de novo myelodysplastic syndromes, secondary myelodysplastic syndromes, previously treated myelodysplastic syndromes
Eligibility Criteria
DISEASE CHARACTERISTICS: Diagnosis of a life-threatening hematologic malignancy, including any of the following: Acute leukemia advanced beyond first remission Acute leukemia in first remission* with very high-risk prognostic features, including any of the following: Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) ALL or acute myeloid leukemia (AML) with 11q23 chromosomal abnormality Hypodiploid ALL Failed to achieve first remission within 1 month after induction therapy Secondary AML Myelodysplastic syndromes with International Prognostic Index score > 1 Chronic myelogenous leukemia in accelerated or blast phase NOTE: *Must be approved by PCC Haploidentical family donor available No suitable HLA-matched related or unrelated donor available No related donor mismatched for a single HLA-A, -B, -C, -DRB1, or -DQB1 antigen available PATIENT CHARACTERISTICS: Age Under 21 Performance status Not specified Life expectancy At least 6 months Hematopoietic Not specified Hepatic SGPT and SGOT < 2 times upper limit of normal (ULN)* Bilirubin < 2 times ULN* NOTE: *Unless due to malignancy Renal Not specified Cardiovascular Ejection fraction ≥ 45% Pulmonary DLCO ≥ 60% of predicted Other Not pregnant or nursing Fertile patients must use effective contraception HIV negative PRIOR CONCURRENT THERAPY: Biologic therapy No second bone marrow transplantation, after a first regimen containing total body irradiation No concurrent growth factors until day 21 post-transplantation Chemotherapy Not specified Endocrine therapy Not specified Radiotherapy See Biologic therapy Surgery Not specified
Sites / Locations
- Fred Hutchinson Cancer Research Center
- Seattle Cancer Care Alliance